41.62 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||41.68 x 1000|
|Ask||42.77 x 900|
|Day's Range||41.48 - 41.93|
|52 Week Range||37.43 - 45.86|
|Beta (3Y Monthly)||0.49|
|PE Ratio (TTM)||21.45|
|Forward Dividend & Yield||1.86 (4.49%)|
|1y Target Est||49.00|
BRIDGEWATER, N.J., Jan. 23, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) to include children age 6 through 35 months. Sanofi Pasteur, the vaccine division of Sanofi, will have the 0.5 mL dose, in addition to the 0.25 mL dose, available for the upcoming 2019-20 season for this expanded age range.
Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
’s failure to get U.K. parliamentary approval for a deal to split the country from the European Union adds significant pressure on companies as they plan for the now greater possibility of an abrupt and disorderly exit. The repudiation has opened up a variety of possible outcomes considered unlikely until recently, from Britain crashing out of the EU without a deal to a new referendum on whether to leave at all. “It’s patients don’t get medicine.” He has spent almost two years planning how to insulate the French drugmaker from a messy Brexit.
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination.
AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
In the past, pharmaceutical companies have attributed high prices to innovation, arguing that new and improved drugs are naturally more expensive . Looking at wholesale data for around 27,000 prescription drugs, Hernandez and her colleagues found that, between 2008 and 2016, brand-name oral prescription drugs rose 9 percent annually, while injectable drugs increased 15 percent per year.
have raised prices of insulin in the US, despite political pressure as diabetics protest and lobby lawmakers over the rising cost of the essential medicine. Sanofi increased the price of its three main insulin brands by between 4.4 per cent and 5.2 per cent last week, while Novo Nordisk increased the price of its insulin products by just under 5 per cent on Tuesday. Depending on the dose and brand, the list prices for insulin products vary between $300 and $400.
just went public on Dec 7, to an immediate "Strong Buy" rating from eight market analysts. In an impressive open, and the biotech sector's largest IPO, the company raised over $600 million to reach a total value of about $7.4 billion. The company takes a novel approach to the creation of new drugs, basing its research on mRNA, the genetic material that transfers instructions from DNA into completed proteins.
Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.
Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. The justices declined to hear Amgen's appeal seeking reinstatement of a jury verdict it won against Regeneron and Sanofi in the dispute in which Amgen accused its rivals of infringing its patents relating to its competing drug Repatha and sought to block sales of Praluent.
Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer. The two companies said the new arrangement would give France's Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while U.S. healthcare group Regeneron retains all rights to its other immuno-oncology discovery and development programmes. Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the immuno-oncology discovery programme costs for the last quarter of 2018.
Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer. The two companies said the new arrangement would give France's Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while U.S. healthcare group Regeneron retains all rights to its other immuno-oncology discovery and development programmes.
Healthcare companies Sanofi and Regeneron have restructured an earlier deal in the immuno-oncology sector, which will result in Sanofi paying its U.S. partner some $582 million. The companies said the new arrangement would give Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline independently, while Regeneron retains all rights to its other immuno-oncology discovery and development programs. Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the immuno-oncology discovery program costs for the last quarter of 2018, and up to $120 million in other development costs.